The only possible new therapy for advanced HCC with a survival benefit over best supportive care in a large controlled trial is the protein kinase inhibitor sorafenib, presented to date only in a meeting abstract [4,22]. This evidence concerns the gene WEE1 and hepatocellular carcinoma.